Treatment

Therapeutic ultrasound for brain disorders

SONOPROBE

At CarThera, we have by-passed the problem of the skull bone by taking advantage of the necessary clinical step of tumor biopsy before any treatment. No clinician worldwide can envision beginning a chemotherapy or radiotherapy treatment without a previous histological diagnosis. We have designed and developed a probe that is able to emit high intensity ultrasound that can be inserted within the tumor as a biopsy needle under local anesthesia.  The probe performs not only the necessary biopsy but also the ultrasound treatment of the tumor in the same procedure under real-time MRI control.

 

SONOCLOUD

Ultrasound emitted at a lower intensity is also able to interact with the biological tissue without destroying it. Using low-intensity pulsed ultrasound, it is possible to temporarily make the blood vessels more porous to drugs. In the brain, the vessels are particularly tight (Blood-Brain Barrier or BBB), preventing the penetration of chemotherapy in the brain and significantly reducing its effectiveness.

At CarThera®, we have developed an implantable medical device containing a low intensity ultrasound transducer, the SonoCloud®, which is able to temporarily open the blood-brain barrier. At each chemotherapy session, the BBB can be opened in order to optimize the penetration of the chemotherapy in the brain while reducing the side effects in the rest of the body.

  • unnamed-2
    unnamed-3

     
  • News CarThera

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.